Skip to content

Repligen RGEN Additional Paid-In Capital

Additional Paid-In Capital at other companies

TEC
Bio-TechneTECH
$1.01B+11.4%
Revvity logo
RevvityRVTY
$1.24B-36.7%
Danaher logo
DanaherDHR
$17.3B+2.7%
Agilent Technologies logo
Agilent TechnologiesA
$5.63B+2.3%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$490.5M+3.1%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$1.97B-0.5%

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's additional paid-in capital?
Repligen (RGEN) reported additional paid-in capital of $1.65B in Q1 2026.
How has Repligen's additional paid-in capital changed year-over-year?
Repligen's additional paid-in capital increased by 2.2% year-over-year, from $1.62B to $1.65B.
What is the long-term trend for Repligen's additional paid-in capital?
Over 5 years (2020 to 2025), Repligen's additional paid-in capital has grown at a 2.5% compound annual growth rate (CAGR), from $1.46B to $1.65B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.